Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 68

Sort by

Sort Order Select

Journal Articles

Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study

Blood Adv (2021) 5 (19): 3862–3872.

https://doi.org/10.1182/bloodadvances.2021004778

Published: 2021

Includes: Supplemental data

Journal Articles

Management of acquired hemophilia A: results from the Spanish registry

María-Eva Mingot-Castellano, Josep Pardos-Gea, Saturnino Haya, José-María Bastida-Bermejo, Dolors Tàssies, Ana Marco-Rico, Ramiro Núñez, Faustino García-Candel, María-Carmen Fernández-Sanchez de Mora, Inmaculada Soto, María-Teresa Álvarez-Román, Susana Asenjo, Marina Carrasco, Rafael Lluch-García, José-Manuel Martín-Antorán, Agustín Rodríguez-Alén, Elena Roselló, Laura Torres-Miñana, Shally Marcellini-Antonio, Ana Moretó-Quinana, José-Antonio Rodríguez-García, Reyes Aguinaco-Culebras, Nieves Alonso-Escobar, Carlos Cervero-Santiago, Núria Fernández-Mosteirín, María-Paz Martínez-Badás, Montserrat Pérez-Sánchez, Rocío Pérez-Montes, Ramón Rodríguez-González, Marisol Uribe-Barrientos, Isabel Socorro Caparrós-Miranda, Miriam Iglesias-Fernández, Ángela Baena, Manuel Rodríguez-López, Ana Sebrango-Sandia, Irene Vázquez-Fernández, Pascual Marco, on behalf of the Acquired Haemophilia Spanish Registry of the Spanish Society of ThrombosisHaemostasis (SETH)

Blood Adv (2021) 5 (19): 3821–3829.

https://doi.org/10.1182/bloodadvances.2021004626

Published: 2021

Includes: Supplemental data

Journal Articles

Bortezomib and rituximab in de novo adolescent/adult CD20-positive, Ph-negative pre-B-cell acute lymphoblastic leukemia

Hasmukh Jain, Manju Sengar, Vasu Babu Goli, Jayashree Thorat, Prashant Tembhare, Dhanlaxmi Shetty, V. N. Avinash Bonda, Lingaraj Nayak, P. G. Subramanian, Bhausaheb Bagal, Nikhil Patkar, Neha Sharma, Himanshi Gupta, Sumeet Gujral

Blood Adv (2021) 5 (17): 3436–3444.

https://doi.org/10.1182/bloodadvances.2020003368

Published: 2021

Journal Articles

Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study

Christian Buske, Wojciech Jurczak, Juan-Manuel Sancho, Edvard Zhavrid, Jin Seok Kim, José-Ángel Hernández-Rivas, Aliaksandr Prokharau, Mariana Vasilica, Rajnish Nagarkar, Larry Kwak, Won-Seog Kim, SangJoon Lee, SungHyun Kim, KeumYoung Ahn, Michinori Ogura

Blood Adv (2021) 5 (17): 3354–3361.

https://doi.org/10.1182/bloodadvances.2021004484

Published: 2021

Includes: Supplemental data

Journal Articles

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma

C. Perry, E. Luttwak, R. Balaban, G. Shefer, M. M. Morales, A. Aharon, Y. Tabib, Y. C. Cohen, N. Benyamini, O. Beyar-Katz, M. Neaman, R. Vitkon, N. Keren-Khadmy, M. Levin, Y. Herishanu, I. Avivi

Blood Adv (2021) 5 (16): 3053–3061.

https://doi.org/10.1182/bloodadvances.2021005094

Published: 2021

Journal Articles

Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study

Mirian Brink, Xaver U. Kahle, Joost S. P. Vermaat, Josee M. Zijlstra, Martine Chamuleau, Marie José Kersten, Müjde Durmaz, Wouter J. Plattel, Pieternella J. Lugtenburg, Wendy Stevens, Rogier Mous, Elisabeth G. E. de Vries, Marjolein W. M. van der Poel, Prashant V. Nannan Panday, Gerwin Huls, Tom van Meerten, Marcel Nijland

Blood Adv (2021) 5 (15): 2958–2964.

https://doi.org/10.1182/bloodadvances.2021004295

Published: 2021

Includes: Supplemental data

Journal Articles

Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma

Blood Adv (2021) 5 (15): 2935–2944.

https://doi.org/10.1182/bloodadvances.2020003985

Published: 2021

Includes: Supplemental data

Journal Articles

Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment

Blood Adv (2021) 5 (15): 2945–2957.

https://doi.org/10.1182/bloodadvances.2021004770

Published: 2021

Includes: Supplemental data

Journal Articles

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

Blood Adv (2021) 5 (13): 2707–2716.

https://doi.org/10.1182/bloodadvances.2020004155

Published: 2021

Includes: Supplemental data

Journal Articles

Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intent–based analysis

Hyehyun Jeong, Hyungwoo Cho, Hyeyeong Kim, Heejung Chae, Jung-Bok Lee, Kyoungmin Lee, Shin Kim, Sang-wook Lee, Jin-Sook Ryu, Kyung Won Kim, Eun Jin Chae, Jooryung Huh, Chan-Sik Park, Dok Hyun Yoon, Cheolwon Suh

Blood Adv (2021) 5 (8): 2142–2152.

https://doi.org/10.1182/bloodadvances.2020003947

Published: 2021

Includes: Supplemental data

Journal Articles

Khurana A, Novo M, Nowakowski GS, et al. Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era. Blood Adv. 2021;5(5):1379-1387.

Blood Adv (2021) 5 (7): 2053.

https://doi.org/10.1182/bloodadvances.2021004700

Published: 2021

Journal Articles

Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases

Ramya Ramaswami, Kathryn Lurain, Mark N. Polizzotto, Irene Ekwede, Kirsta Waldon, Seth M. Steinberg, Ralph Mangusan, Anaida Widell, Adam Rupert, Jomy George, Priscila H. Gonçalves, Vickie A. Marshall, Denise Whitby, Hao-Wei Wang, Stefania Pittaluga, Elaine S. Jaffe, Richard F. Little, Thomas S. Uldrick, Robert Yarchoan

Blood Adv (2021) 5 (6): 1660–1670.

https://doi.org/10.1182/bloodadvances.2020004058

Published: 2021

Includes: Supplemental data

Journal Articles

Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines

Alden A. Moccia, Kimberly Schaff, Ciara Freeman, Paul J. Hoskins, Richard J. Klasa, Kerry J. Savage, Tamara N. Shenkier, Randy D. Gascoyne, Joseph M. Connors, Laurie H. Sehn

Blood Adv (2021) 5 (5): 1483–1489.

https://doi.org/10.1182/bloodadvances.2020002982

Published: 2021

Includes: Supplemental data

Journal Articles

Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era

Arushi Khurana, Mattia Novo, Grzegorz S. Nowakowski, Kay M. Ristow, Robert J. Spinner, Christopher H. Hunt, Rebecca L. King, Daniel H. Lachance, Thomas M. Habermann, Ivana N. Micallef, Patrick B. Johnston

Blood Adv (2021) 5 (5): 1379–1387.

https://doi.org/10.1182/bloodadvances.2020003666

Published: 2021

Includes: Supplemental data

Journal Articles

End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA

Lale Kostakoglu, Maurizio Martelli, Laurie H. Sehn, David Belada, Angelo-Michele Carella, Neil Chua, Eva Gonzalez-Barca, Xiaonan Hong, Antonio Pinto, Yuankai Shi, Yoichi Tatsumi, Andrea Knapp, Federico Mattiello, Tina Nielsen, Deniz Sahin, Gila Sellam, Mikkel Z. Oestergaard, Umberto Vitolo, Marek Trněný

Blood Adv (2021) 5 (5): 1283–1290.

https://doi.org/10.1182/bloodadvances.2020002690

Published: 2021

Includes: Supplemental data

Journal Articles

A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial

Blood Adv (2021) 5 (4): 984–993.

https://doi.org/10.1182/bloodadvances.2020002567

Published: 2021

Includes: Supplemental data

Journal Articles

Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma

Panayiotis Panayiotidis, George A. Follows, Luigina Mollica, Arnon Nagler, Muhit Özcan, Armando Santoro, Don Stevens, David Trevarthen, Florian Hiemeyer, Jose Garcia-Vargas, Barrett H. Childs, Pier Luigi Zinzani, Martin Dreyling

Blood Adv (2021) 5 (3): 823–828.

https://doi.org/10.1182/bloodadvances.2020002910

Published: 2021

Includes: Supplemental data

Journal Articles

Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models

Blood Adv (2020) 4 (18): 4451–4462.

https://doi.org/10.1182/bloodadvances.2020002546

Published: 2020

Includes: Supplemental data

Journal Articles

Primary human herpesvirus 8–negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis

Daisuke Kaji, Yasunori Ota, Yasuharu Sato, Koji Nagafuji, Yasunori Ueda, Masataka Okamoto, Yasushi Terasaki, Naoko Tsuyama, Kosei Matsue, Tomohiro Kinoshita, Go Yamamoto, Shuichi Taniguchi, Shigeru Chiba, Koichi Ohshima, Koji Izutsu

Blood Adv (2020) 4 (18): 4442–4450.

https://doi.org/10.1182/bloodadvances.2020002293

Published: 2020

Includes: Supplemental data

Journal Articles

Phase 1/2a study of 177 Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma

Arne Kolstad, Tim Illidge, Nils Bolstad, Signe Spetalen, Ulf Madsbu, Caroline Stokke, Johan Blakkisrud, Ayca Løndalen, Noelle O'Rourke, Matthew Beasley, Wojciech Jurczak, Unn-Merete Fagerli, Michal Kaščák, Mike Bayne, Aleš Obr, Jostein Dahle, Lisa Rojkjaer, Veronique Pascal, Harald Holte

Blood Adv (2020) 4 (17): 4091–4101.

https://doi.org/10.1182/bloodadvances.2020002583

Published: 2020

Includes: Supplemental data

NARROW

Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study

Management of acquired hemophilia A: results from the Spanish registry

Bortezomib and rituximab in de novo adolescent/adult CD20-positive, Ph-negative pre-B-cell acute lymphoblastic leukemia

Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma

Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study

Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma

Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intent–based analysis

Khurana A, Novo M, Nowakowski GS, et al. Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era. Blood Adv. 2021;5(5):1379-1387.

Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases

Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines

Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era

End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA

A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial

Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma

Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models

Primary human herpesvirus 8–negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis

Phase 1/2a study of 177 Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only